TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

被引：41

作者：

Gram, Dorte X. ^{[1
]}

Holst, Jens J. ^{[2
]}

Szallasi, Arpad ^{[3
]}

机构：

[1] Pila Pharma, Malmo, Sweden

[2] Univ Copenhagen, Panum Inst, Copenhagen, Denmark

[3] Baptist Med Ctr, Jacksonville, FL USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2017年 / 23卷 / 11期

关键词：

GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; SUBSTANCE-P; INSULIN-SECRETION; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHY; INFLAMMATORY MARKERS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; ISLET INFLAMMATION;

D O I：

10.1016/j.molmed.2017.09.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.

引用

页码：1002 / 1013

页数：12

共 50 条

[1] TRPV1: A Potential Therapeutic Target for Myocardial Infarction?
Cao, Lu
Cheng, Lihua
Xu, Jing
CARDIOLOGY, 2017, 136 (03) : 156 - 156
[2] TRPV1: A potential target for antiepileptogenesis
Fu, Min
Xie, Zuoping
Zuo, Huancong
MEDICAL HYPOTHESES, 2009, 73 (01) : 100 - 102
[3] Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity
Andrei V. Derbenev
Andrea Zsombok
Seminars in Immunopathology, 2016, 38 : 397 - 406
[4] The TRPV1 vanilloid receptor: A target for therapeutic intervention
Breitenbucher, JG
Chaplan, SR
Carruthers, NI
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 185 - 198
[5] Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity
Derbenev, Andrei V.
Zsombok, Andrea
SEMINARS IN IMMUNOPATHOLOGY, 2016, 38 (03) : 397 - 406
[6] TRPV1: a therapeutic target for novel analgesic drugs?
Szallasi, Arpad
Cruz, Francisco
Geppetti, Pierangelo
TRENDS IN MOLECULAR MEDICINE, 2006, 12 (11) : 545 - 554
[7] Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease
Robbins, Nathan
Koch, Sheryl E.
Rubinstein, Jack
TRANSLATIONAL RESEARCH, 2013, 161 (06) : 469 - 476
[8] IS TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 (TRPV1) A NEW TARGET FOR CARDIOPROTECTION?
AL-Mawla, R.
Paita, L.
Bidault-Ducreux, S.
Chouabe, C.
Durand, A.
Augeul, L.
Dupre-Aucouturier, S.
Bonvallet, R.
Ovize, M.
Van Coppenolle, F.
JOURNAL OF HYPERTENSION, 2016, 34 : E212 - E213
[9] TRPV1: A Potential Therapeutic Target for Inflammation and Pain in Parkinson's disease (PD)
Song, S. J.
Kim, Y. E.
MOVEMENT DISORDERS, 2024, 39 : S154 - S155
[10] TRPV1 Signaling: Mechanistic Understanding and Therapeutic Potential
Xia, Rong
Samad, Tarek A.
Btesh, Joan
Jiang, Lin-Hua
Kays, Ibrahim
Stjernborg, Louise
Dekker, Niek
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (17) : 2180 - 2191

← 1 2 3 4 5 →